In a report released today, Terence Flynn from Morgan Stanley maintained a Buy rating on BioNTech SE (BNTX – Research Report), with a price ...

PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the ...

BioNTech SE (NASDAQ:BNTX), a biotechnology company renowned for its mRNA technology platform and COVID-19 vaccine success, is navigating a crucial phase in its evolution. With a market capitalization ...

Atomi Financial Group Inc. raised its stake in BioNTech SE (NASDAQ:BNTX – Free Report) by 6.7% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional ...

Get the Real Story Behind Every Major Earnings Report What To Know ... According to data from Benzinga Pro, BNTX has a 52-week high of $131.49 and a 52-week low of $76.53.

So it is worth checking the past earnings trajectory of BioNTech, (below). Of course, keep in mind that there are other factors to consider, too. NasdaqGS:BNTX Earnings and Revenue Growth January 7th ...